Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-06-05
2000-11-14
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514185, 424675, 424678, 424686, A01N 5504
Patent
active
061470708
ABSTRACT:
Methods and compositions of matter are provided that enable a phased reduction of body iron stores to near a iron deficiency level, and thereafter maintain the body iron stores at that level by reducing further iron accumulation. In a first phase, a patient's body iron stores are reduced to a level of near iron deficiency by regular periodic phlebotomy or use of pharmacological agents, such as iron chelators, for example, over a period of six to twelve months. In a second phase, ingested iron absorption is controlled using an oral dose, taken at mealtimes, of compound comprising a calcium salt and salts of phytic acid, without or without zinc, or by continuing, less frequent phlebotomy.
REFERENCES:
patent: 4952568 (1990-08-01), Sawai et al.
patent: 5162313 (1992-11-01), Kappas et al.
patent: 5190970 (1993-03-01), Pan et al.
patent: 5223494 (1993-06-01), Kappas et al.
patent: 5298525 (1994-03-01), Yoon et al.
patent: 5762936 (1998-06-01), Ronzio et al.
patent: 5990153 (1999-11-01), Wood et al.
Cutler, P., "Deferoxamine Therapy in High-Ferritin Diabetes," Diabetes, vol. 38, Oct. 1989, pp. 1207-1210.
Weintraub et al., "The Treatment of Hemochromatosis by Phlebotomy", Med. Clin. North Am., vol. 50, No. 6, 1966, pp. 1579-1590.
Cecil Textbook of Medicine, 19th edition, W.B. Saunders Co., p. 1135, 1993.
Remington: The Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Chapter 54, p. 934, 1995.
Balla, G., et al. "Hemin: A Possible Physiological Mediator of Low Density Lipoprotein Oxidation and Endothelial Injury," Arteriosclerosis and Thrombosis, vol. 11, No. 6, Nov./Dec. 1991, pp. 1700-1711.
Bennett, P.H., et al., "Definition, Diagnosis, and Classification of Diabetes Mellitus and Impaired Glucose Tolerance," Chapter 11, Joslin's Diabetes Mellitus, 13th Edition, 1994, pp. 193-200.
Blake, D.R., et al., "Cerebral and Ocular Toxicity Induced by Desferrioxamine," Quarterly Journal of Medicine, New Series 56, No. 219, Jul. 1985, pp. 345-355.
Boni, R.E., et al. "Tin-Mesoporphyrin Inhibits Heme Oxygenase Activity and Heme-Iron Absorption in the Intestine," Pharmacology, vol. 47, 1993, pp. 318-329.
Comiancini, L., et al., "Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients," Diabetes, vol. 17, Jan. 1998, pp. 130-133.
Dymock, I.W., "Observations on the Pathogenesis, Complications and Treatment of Diabetes in 115 Cases of Haemochromatosis," The American Journal of Medicine, vol. 52, Feb. 1972, pp. 203-209.
Facchini, F., et al., "Light-to-Moderate Alcohol Intake is Associated With Enhanced Insulin Sensitivity," Diabetes Care, vol. 17, No. 2, Feb. 1994, pp. 115-119.
Facchini, F., et al., "Relation Between Dietary Vitamin Intake and Resistance to Insulin-Mediated Glucose Disposal in Healthy Volunteers," Am. J. Clin. Nutr., vol. 63, 1996, pp. 946-949.
Fernandez-Real, J., et al., "Serum Ferritin as a Component of the Insulin Resistance Syndrome," Diabetes Care, vol. 21, No. 1, Jan. 1998, pp. 62-68.
Finch, C.A. et al., "Effect of Blood Donation on Iron Stores as Evaluated by Serum Ferritin," Blood, vol. 50, 1977, pp. 441-447.
Ghidoni, A., et al., "Effect of Desferrioxamine Methansulphonate (DFOM) on Glucose Uptake by Rat Epididymal Adipose Tissue (30958)," Proceedings of the Society for Experimental Biology and Medicine, vol. 121, 1996, pp. 1039-1041.
Hallberg, L., et al., "Calcium: Effect of Different Amounts on Nonheme- and Heme-iron Absorption in Humans," Am. J. Clin. Nutr., vol. 53, 1991, pp. 112-119.
Hallberg, L., et al., "Iron Absorption in Man: Ascorbic Acid and Dose-Dependent Inhibition by Phytate," Am. J. Clin. Nutr., vol. 49, 1989, pp. 140-144.
Hunt, J.V., et al., "Oxidative Glycation and Free Radical Production: A Causal Mechanism of Diabetic Complications," Free Rad. Res. Comms., vols. 12-13, 1991, pp. 115-123.
Jeppesen, J., et al., "Individuals with High Total Cholesterol/HDL Cholesterol Ratios are Insulin Resistant," Journal of Internal Medicine, vol. 243, 1998, pp. 293-298.
Lillioja, S., et al., "Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus," The New England Journal of Medicine, vol. 329, No. 27, pp. 1988-1992.
Lin, J., et al., "Convulsive Syncope in Blood Donors," Annals of Neurology, vol. 11, No. 5, May 1982, pp. 525-528.
Matthews, A.J., et al., "Iron and Atherosclerosis: Inhibition by the Iron Chelator Deferiprone," Journal of Surgical Research, vol. 79, No. 1, Nov. 1997, pp. 35-40.
Meyers, D.G., et al., "Possible Association of a Reduction in Cardiovascular Events with Blood Donation," Hematology, 1978, pp. 188-193.
Nitenberg, A., et al., "Coronary Artery Responses to Cold Pressor Test and Flow Velocity Increase is Improved by Desferrioxamine but Not L-Arginine in Diabetic Patients," Archives Des Maladies Du Coeur et Des Vaisseaux, vol. 90, No. 8, 1997, pp. 1037-1041.
Olefsky, J.M., et al., "Reappraisal of the Role of Insulin in Hypertriglyceridemia," The American Journal of Medicine, vol. 57, Oct. 1974, pp. 551-560.
Paolisso, G., et al., "Pharmacologic Doses of Vitamin E Improve Insulin Action in Healthy Subjects and Non-Insulin-Dependent Diabetic Patients," Am. J. Clin. Nutr., vol. 57, 1993, pp. 650-656.
Pieper, G.M., et al., "Diabetes-Induced Endothelial Dysfunction is Prevented by Long-Term Treatment with the Modified Iron Chelator, Hydroxyethyl Starch Conjugated-Deferoxamine," Journal of Cardiovascular Pharmacology, vol. 30, 1997, pp. 734-737.
Potashnik, R., et al., "Regulation of Glucose Transport and GLUT-1 Expression by Iron Chelators in Muscle Cells in Culture," The American Physiological Society, 1995, pp. E1052-E1058.
Reaven, G.M., "Pathophysiology of Insulin Resistance in Human Disease," Physiological Reviews, vol. 75, No. 3, Jul. 1995, pp. 473-486.
Reaven, G.M., "Study of the Relationship Between Glucose and Insulin Responses to an Oral Glucose Load in Man," Diabetes, vol. 17, No. 9, Sep. 1968, pp. 560-569.
Reaven, G.M., et al., "Hypertension and Associated Metabolic Abnormalities--The Role of Insulin Resistance and the Sympathoadrenal System," The New England Journal of Medicine, vol. 334, No. 6, Feb. 8, 1996, pp. 374-381.
Reddy, M.B., et al., "The Influence of Different Protein Sources on Phytate Inhibition of Nonheme-Iron Absorption in Humans," Am. J. Clin. Nutr., vol. 63, 1996, pp. 203-207.
Redmon, J.B., et al., "No Effect of Deferoxamine Therapy on Glucose Homeostasis and Insulin Secretion in Individuals With NIDDM and Elevated Serum Ferritin," Diabetes, vol. 42, Apr. 1993, pp. 544-549.
Spencer, C.M., et al, "Troglitazone," Drugs, vol. 54, No. 1, Jul. 1997, pp. 89-101.
Thompson, L.U., "Phytic Acid and Calcium Affect the In Vitro Rate of Navy Bean Starch Digestion and Blood Glucose Response in Humans," Am. J. Clin. Nutr., vol. 46, 1987, pp. 467-473.
Tuomainen, T., et al., "Body Iron Stores Are Associated With Serum Insulin and Blood Glucose Concentrations," Diabetes Care, vol. 20, No. 3, Mar. 1997, pp. 426-428.
Yadrick, M.K., et al., "Iron, Copper, and Zinc Status: Response to Supplementation with Zinc or Zinc and Iron in Adult Females," Am. J. Clin. Nutr., vol. 49, 1989, pp. 145-149.
Yoshioka, T., et al., "Studies on Hindered Phenols and Analogues. 1. Hypolipidemic and Hypoglycemic Agents with Ability to Inhibit Lipid Peroxidation," J. Med. Chem., vol. 32, 1989, pp. 421-428.
Weintraub, L.R., "The Treatment of Hemochromatosis by Phlebotomy," Med. Clin. North Am., vol. 50, No. 6, 1966, pp. 1579-1590.
"Deferoxamine Mesylate: Heavy Metal Antagonists," AHFS Drug Information, 95, pp. 2080-2081, 1995.
"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus," Diabetes Care, vol. 20, No. 7, Jul. 1997, pp. 1183-1197.
Jones Dwayne C.
Pisano Nicola A.
LandOfFree
Methods and compositions for controlling iron stores to treat an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for controlling iron stores to treat an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for controlling iron stores to treat an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065598